TSPO and esophagus carcinoma in situ: To further validate the differential expression of TSPO in esophageal cancer tissues, we established a mouse model of esophageal carcinoma in situ and obtained esophageal tissues at 18 weeks, which were subsequently subjected to hematoxylin and eosin (HE) staining and immunohistochemical (IHC) staining analysis (Figure 9).